Results

1–6 of 6 results for abicipar

Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020
Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation
Tarek S. Hassan, MD, FASRS
Annual Meeting Talks
2020
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Updates from the Field
2019
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients With nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Annual Meeting Talks
2019
Abicipar Pegol Phase 3 AMD Studies
Pravin U. Dugel, MD
Updates from the Field
2017